In light of the difficulties of culturing IDH1 mutated patient-derived glioma cells in vitro [27,28] and the lack of patient-derived IDH mutant in vitro and in vivo models [29,30], our approach provides a suitable alternative to investigate IDH1R132H-dependent alterations in tumor cell metabolism. The gene discussed is IDH1; the disease is central nervous system cancer.